GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

Zacks Investment Research • 6 hours ago

GSK beats third-quarter profit estimates, keeps annual targets

GSK beat third-quarter sales ‌and profit expectations on Wednesday, driven by demand for specialty medicines after the drugmaker began a strategic overhaul under CEO Luke Miels to accelerate growth and prepare for looming patent losses.

Reuters • Oct 28, 2026

GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat

GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.

Benzinga • Oct 28, 2026

GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat

GSK stock toppled early Wednesday after the company's third-quarter vaccine sales fell short, outshining a solid topline.

Investors Business Daily • Oct 28, 2026

What GSK (GSK) Said on Its Q3 Earnings Call

GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%.

MarketBeat • Oct 28, 2026

GSK Sales Get Boost From Specialty Medicines

The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.

WSJ • Oct 28, 2026

GSK plc (GSK) Q3 2026 Earnings Call Transcript

GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director Tony Wood - Chief Scientific Officer and Head of R&D Nina Mojas - President of Global Product Strategy Julie Brown - CFO & Executive Director David Redfern - President of Corporate Development Conference Call Participants James Gordon - Barclays Bank PLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Michael Leuchten - Jefferies LLC, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Matthew Weston - UBS Investment Bank, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Presentation Jeff McLaughlin VP of Investor Relations & Interim Head of Investor Relations Welcome, everyone, and thanks for joining GSK's Q3 2026 results.

Seeking Alpha • Oct 28, 2026

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.

Zacks Investment Research • Oct 28, 2026

GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.

Zacks Investment Research • Oct 28, 2026

GSK: Why I'm Still Bullish After Strong Q3 Results

GSK plc delivered strong results today. In the third quarter, revenue and non-GAAP EPS grew 5.7% and 8.2% quarter-on-quarter, respectively. Cabenuva, GSK's long-acting HIV treatment, generated $641 million in sales, up 35.2% year over year.

Seeking Alpha • Oct 28, 2026